TMCnet News
Tetraphase Pharmaceuticals to Present Antibiotics Pipeline Data at ASM Microbe 2017Eleven Abstracts Selected for Presentation, Including Four Highlighting Pharmacokinetic and Global Surveillance Data for Eravacycline TP-6076 Phase 1 Single-Ascending Dose Data Selected for Oral Presentation; TP-271 Phase 1 Single-Ascending Dose Data to be Featured in Poster Presentation WATERTOWN, Mass., May 22, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced upcoming data presentations at the American Society for Microbiology (ASM) Microbe 2017 Annual Meeting, taking place June 1-5, 2017 in New Orleans, LA. In total, eleven presentations will be given including pharmacokinetic and global surveillance data for the Company's phase 3 antibiotic drug candidate, eravacycline, one oral presentation highlighting TP-6076 phase 1 single-ascending dose (SAD) study results, one poster presentation featuring TP-271 SAD study results, and additional pipeline program data. “We continue to be pleased with the additional supportive data generated for eravacycline which shows consistent potency against drug-resistant bacteria in ongoing global surveillance studies,” said Guy Macdonald, President and Chief Executive Officer of Tetraphase. “We also have been highly encouraged by the preclinical profiles observed to date with both TP-271 and TP-6076, and we look forward to sharing the data from our first-in-human, phase 1 SAD studies for each of these promising candidates with the medical community at ASM Microbe this year.” Details for the data presentations at ASM Microbe 2017 are as follows: Eravacycline Data Presentations Poster #54: Activity of Eravacycline Against Carbapenem Resistant Enterobacteriaceae and Acinetobacter baumannii Poster #189: Pharmacokinetics-Pharmacodynamics (PK-PD) of Efficacy for Eravacycline Against Escherichia coli in an In Vitro Infection Model Poster #190: Compartmental Pharmacokinetics of Eravacycline following Intravenous Administration in Rabbits Poster #191: PK/PD of the Novel Fluorocycline Eravacycline is Efficacious in a Murine E. coli Thigh Model. Clinical Pipeline Data Presentations Oral Presentation #8: Safety, Tolerability and Pharmacokinetics of Single Doses of TP-6076, a Novel Fully Synthetic Tetracycline, in a Phase 1 Study Poster #198: Safety, Tolerability and Pharmacokinetics of Single Intravenous Doses of TP-271, a Novel Fluorocycline Antibiotic Preclinical Pipeline Data Presentations Poster #36: The Novel Fluorocycline TP-271 is Efficacious in a Nonhuman Primate Model of Inhalation Anthrax. Poster #94: The Novel Fluorocycline TP-271 is Efficacious in a Murine A. baumannii Pneumonia Model. Poster #332: TP-6076, A Fully Synthetic Tetracycline Antibacterial Agent, Is Highly Potent against a Broad Range of Pathogens, including Carbapenem-resistant Enterobacteriaceae Multidrug-Resistant Infection Prevalence Data Presentations Poster #95: Prevalence of Multidrug-Resistant Acinetobacter baumannii (MDR AB) by ICU Status and Setting in USA Hospitals in 2015-2016: A Multicenter Study Poster #100: Prevalence of Multidrug-Resistance (MDR) in Enterobacteriaceae (ENT) by ICU Status and Setting in USA Hospitals in 2015-2016: A Multicenter Study ASM Microbe 2017 is the integration of two of the American Society of Microbiology’s meetings: the General Meeting and ICAAC (Interscience Conference on Antimicrobial Agents and Chemotherapy). Full abstracts can be found on the ASM Microbe website at http://www.asmmicrobe.org/. About Tetraphase Pharmaceuticals, Inc. Investor Contacts: Tetraphase Pharmaceuticals Teri Dahlman 617-600-7040 [email protected] Argot Partners Maeve Conneighton 206.899.4940 [email protected] Media Contact: Sam Brown Inc. Mike Beyer 312-961-2502 [email protected] |